In animal experiment studies, Chinese researchers have found that a metabolite of the antiviral drug Remdesivir called GS-441524 could help inhibit the severe acute respiratory syndrome coronavirus 2 ...

Results from a preclinical study evaluating the impact of resistance mutations on the in vitro antiviral activity of GS-6207 were also presented. In this in vitro study, GS-6207 was not affected by ...

Results from a multinational phase II study have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with nonalcoholic steatohepatitis (NASH -- the ...

The combination of a chemotherapy doublet (gemcitabine plus capecitabine) with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma: The TARGET study.

Change Does Not Affect Ongoing “All Oral” Clinical Trials Evaluating Multiple Direct-Acting Antivirals in Combination FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today ...

A prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients ...

BOSTON--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced data from clinical and preclinical studies exploring the use of GS-6207, an investigational, novel, first-in-class ...

Vienna, Austria, Thursday 15 April: Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 ...